Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)

Kristina Sonnevi

Solna, AB, SE 
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Solna, AB, SE 
OverviewLocationsClinical Research

Overview

Kristina Sonnevi practices in Solna, Sweden. Ms. Sonnevi is rated as an Advanced expert by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Her top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Splenectomy.

Her clinical research consists of co-authoring 31 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 6 articles in the study of Diffuse Large B-Cell Lymphoma (DLBCL).

Gender
Female

Locations

Solna, AB, Sweden
Other Locations
Stockholm, AB, Sweden
Karolinska Institutet
Huddinge, AB, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2024
Intervention Type: Drug
Study Drug: Acalabrutinib-Rituximab
Study Phase: Phase 2
Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Enrollment Status: Unknown
Publish Date: October 13, 2021
Intervention Type: Drug
Study Drug: Venetoclax
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

31 Total Publications

A 30-minute intravenous infusion of rituximab is safe and cost-effective (SpeedR).
A 30-minute intravenous infusion of rituximab is safe and cost-effective (SpeedR).
Journal: Annals of hematology
Published: May 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Sonnevi's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile